吉西他滨联合顺铂加地塞米松治疗复发性或难治性非霍奇金淋巴瘤

目的：观察吉西他滨（GEM）联合顺铂（DDP）、地塞米松（DXM）组成的GDP方案治疗复发性或难治性非霍奇金淋巴瘤（NHL）的疗效和毒副反应。方法：2005年10月～2007年1月我科收治的13例复发性或难治性NHL患者,分别为弥漫大B细胞淋巴瘤（BCEL-1）11例和外周T细胞淋巴瘤（TCEL-1）2例,给予吉西他滨1000mg/m^2,d1、d8,静脉滴注;顺铂25mg/m^2,d1～d3,静脉滴注;地塞米松20mg/d,d1～d5,口服。21天为1周期。2个周期后评价疗效,并随访疾病进展情况。结果：13例患者中,9例获缓解（69.2%）,其中完全缓解4例（30.8%）,部分缓解5例（38.5%）。在可随访评价的12例患者中位TTP7.9个月（95%CI：7.4～9.4个月）。毒副反应主要为骨髓抑制和轻中度的消化道反应。骨髓抑制表现为Ⅲ～Ⅳ度白细胞下降3例,Ⅲ度血小板下降4例。结论：吉西他滨联合顺铂、地塞米松组成的GDP方案治疗复发性或难治性NHL的近期疗效较好,安全性高。

Gemcitabine in combination with cisplatin and dexamethasone in the treatment of relapsed or refractory non-Hodgkin's lymphoma

Objective：To evaluate the efficacy and toxicity of gemcitabine combined with cisplatin and dexamethasone in the treatment of patients with relapsed or refractory non-Hodgkin＇s lymphoma.Methods：Thirteen patients with histologically confirmed relapsed or refractory non-Hodgkin＇s lymphoma were enrolled in this study.The chemotherapy regimen consisted gemcitabine（1g/m^2,days 1 and 8）,cisplatin（25mg/m^2,day 1-3） and dexamethasone（20mg/d,day 1-5） given every three weeks,every patients received at least for 2 cycles.Results：Of 13 patients,9 patients（69.2%） showed response including 4 patients（30.8%） having complete response and 5 patients（38.5%） partial response.The median time to progression of disease for twelve patients that were received the follow-up was 7.9 months（95%CI：7.4-9.4 months）.Drug related toxic effects were mild gastrointestinal reactions in most patients as well as mild bone marrow depression in some patients such as neutropenia,thrombocytopenia.Conclusion：The combination of gemcitabine,cisplatin and dexamethasone possesses better short-term efficacy,acceptable toxicity,and obvious alleviation of symptoms related to the disease.This protocol is worthy to be warranted as salvage for relapsed or refractory non-Hodgkin＇s lymphoma.